Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors

In EGFR-treatment naive NSCLC patients, high-level MET amplification is detected in approximately 2–3% and is considered as adverse prognostic factor. Currently, clinical trials with two different inhibitors, capmatinib and tepotinib, are under way both defining different inclusion criteria regardin...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Comput Struct Biotechnol J
Prif Awduron: Heydt, Carina, Becher, Ann-Kathrin, Wagener-Ryczek, Svenja, Ball, Markus, Schultheis, Anne M., Schallenberg, Simon, Rüsseler, Vanessa, Büttner, Reinhard, Merkelbach-Bruse, Sabine
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Research Network of Computational and Structural Biotechnology 2019
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6861603/
https://ncbi.nlm.nih.gov/pubmed/31762957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.csbj.2019.09.003
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg